



## Twist Bioscience Announces Presentations and User Group Meeting at PEGS Boston 2019

April 1, 2019

-- Aaron Sato, Ph.D., Chief Scientific Officer of Twist Biopharma, to Deliver Keynote Address --

-- User Group Meeting to Feature Scientists Discussing Applications of Twist Libraries to Discover and Optimize High Quality Antibody Drugs --

SAN FRANCISCO--(BUSINESS WIRE)--Apr. 1, 2019-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced five presentations at PEGS (The Essential Protein Engineering Summit) taking place April 8-12, 2019 at the Seaport World Trade Center in Boston. The presentations include an overview of Twist Biopharma as well as proof-of-concept data for its GPCR library and antibody optimization solutions from Aaron Sato, Ph.D., Chief Scientific Officer of Twist Biopharma, and four poster presentations.

The presentations will occur on Monday, April 8<sup>th</sup>. The company will also host a User Group Meeting on Wednesday, April 10<sup>th</sup> at 6:45 pm ET. Full event information can be found [here](#).

The details for the presentations are as follows:

### Presentation at PEGS

Date: Monday, April 8, 2019

Time: 1:50 pm - 2:20 pm

Location: Auditorium

Speaker: Aaron Sato, Ph.D., CSO, Twist Biopharma

Talk Title: Synthetic DNA Technologies Enable Antibody Discovery and Optimization

### Poster Presentations

Date: Monday, April 8, 2019

Time: 5:40 pm – 7:15 pm

Location: Commonwealth Hall

Poster Session: A

*Poster Number: A103*

Precision Synthesis of Variant Libraries Enables Comprehensive Interrogation of Single Site Variant Space

*Poster Number: A104*

A High-Throughput Platform to Develop Highly Potent and Functional Antibodies Against G-Protein Coupled Receptors

*Poster Number: A105*

Twist Bioscience's Silicon-Based DNA Synthesis Platform Enables the Construction of Focused Variant Libraries with Unprecedented Precision

*Poster Number: A106*

Rapid Optimization and Humanization of an Anti-PD1 Antibody

### About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on [Twitter](#) | [Facebook](#) | [LinkedIn](#) | [YouTube](#)

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190401005252/en/>

Source: Twist Bioscience Corporation

Twist Investor Contact:

Argot Partners

Maeve Conneighton

212-600-1902

[maeve@argotpartners.com](mailto:maeve@argotpartners.com)

Twist Media Contact:

Angela Bitting

925-202-6211

[media@twistbioscience.com](mailto:media@twistbioscience.com)